PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsSulfacetamide
Sulfacetamide
Blephamide, Cetapred, Fml-s, Gyne-sulf, Klaron, Metimyd, Predamide, Predsulfair, Sulfacetamide, Sulphrin, Sultrin, Trysul, Vagilia, Vasocidin (sulfacetamide) is a small molecule pharmaceutical. Sulfacetamide was first approved as Blephamide on 1982-01-01. It is used to treat bacterial infections, bacterial skin diseases, corneal ulcer, ear diseases, and seborrheic dermatitis amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
otorhinolaryngologic diseasesD010038
eye diseasesD005128
skin and connective tissue diseasesD017437
Trade Name
FDA
EMA
Klaron, Sulfacetamide (discontinued: Bleph, Cetamide, Isopto cetamide, Sulamyd, Sulf, Sulfacetamide, Sulten)
Combinations
Sulfacetamide prednisolone (discontinued: Blephamide, Cetapred, Fml-s, Gyne-sulf, Isopto cetapred, Metimyd, Predamide, Sulfacetamide prednisolone, Sulphrin, Sulster, Sultrin, Triple sulfa, Trysul, Vagilia, Vasocidin)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Sulfacetamide
+
Sulfathiazole)
+
Triple sulfa (sulfabenzamide
Tradename
Company
Number
Date
Products
SULTRINJohnson & JohnsonN-005794 DISCN1982-01-01
2 products
Hide discontinued
Prednisolone sodium phosphate
+
Sulfacetamide sodium
Tradename
Company
Number
Date
Products
VASOCIDINNovartisN-018988 DISCN1988-08-26
1 products, RLD
Hide discontinued
Sulfacetamide sodium
Tradename
Company
Number
Date
Products
KLARONBausch Health CompaniesN-019931 RX1996-12-23
1 products, RLD, RS
Show 1 discontinued
Prednisolone acetate
+
Sulfacetamide sodium
Tradename
Company
Number
Date
Products
BLEPHAMIDEAllerganN-012813 DISCN1982-01-01
1 products, RLD
METIMYDMerck & CoN-010210 DISCN1982-01-01
2 products
Hide discontinued
Fluorometholone
+
Sulfacetamide sodium
Tradename
Company
Number
Date
Products
FML-SAllerganN-019525 DISCN1989-09-29
1 products
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
avarunapproved drug other2023-08-30
avar lsunapproved drug other2023-08-30
avar-eunapproved drug other2023-09-26
avar-e greenunapproved drug other2023-11-07
avar-e lsunapproved drug other2023-03-22
blephamideNew Drug Application2013-11-15
cetamide isopto cetamide2006-11-20
clenia plusunapproved drug other2024-07-11
clindamycin 1% / sodium sulfacetamide monohydrate 5% / tretinoin 0.025%unapproved drug other2019-05-03
exact-rx sodium sulfacetamide and sulfer 10%/5% cleanserunapproved drug other2023-10-23
Show 52 more
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
corneal ulcer—D003320H16.0
bacterial infections—D001424A49
bacterial skin diseases—D017192—
trachoma—D014141A71
ear diseasesEFO_1001455D004427H93.9
seborrheic dermatitisHP_0001051D012628L21
leukemia—D007938C95
brain neoplasmsEFO_0003833D001932C71
atopic dermatitisEFO_0000274D003876L20
ulcerative colitisEFO_0000729D003093K51
Show 26 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
D: Dermatologicals
— D10: Anti-acne preparations
— D10A: Anti-acne preparations for topical use
— D10AF: Antiinfectives for treatment of acne
— D10AF06: Sulfacetamide
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01A: Antiinfective ophthalmologics
— S01AB: Sulfonamides, ophthalmologic antiinfectives
— S01AB04: Sulfacetamide
HCPCS
No data
Clinical
Clinical Trials
5 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Meibomian gland dysfunctionD000080343—H02.88———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast neoplasmsD001943EFO_0003869C50——1——1
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
OsteomyelitisD010019EFO_0003102M861————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369—C80————11
Neoplasm metastasisD009362EFO_0009708—————11
Neoplastic processesD009385——————11
Pathologic processesD010335——————11
Prostatic neoplasmsD011471—C61————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameSulfacetamide
INNsulfacetamide
Description
Sulfacetamide is a sulfonamide that is sulfanilamide acylated on the sulfonamide nitrogen. It has a role as an antimicrobial agent, an antiinfective agent, an EC 2.5.1.15 (dihydropteroate synthase) inhibitor and an antibacterial drug. It is a substituted aniline and a N-sulfonylcarboxamide. It is functionally related to a sulfanilamide. It is a conjugate acid of a sulfacetamide(1-).
Classification
Small molecule
Drug classantimicrobials (sulfonamides derivatives)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CC(=O)NS(=O)(=O)c1ccc(N)cc1
Identifiers
PDB—
CAS-ID144-80-9
RxCUI—
ChEMBL IDCHEMBL455
ChEBI ID63845
PubChem CID5320
DrugBankDB00634
UNII ID4965G3J0F5 (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 1,336 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
720 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use